ADC man­u­fac­tur­ing will like­ly stay with es­tab­lished CD­MOs due to high bar­ri­er to mar­ket en­try

An­ti­body-drug con­ju­gate (AD­Cs) man­u­fac­tur­ing is like­ly to re­main among CD­MOs al­ready mak­ing them due to de­mand­ing mar­ket en­try re­quire­ments, ex­ec­u­tives in the ADC space said …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER